Annual Report 2008

"The 2007/08 financial year was an important one for the completion of key product and commercial milestones. In addition it was the Company’s first full year of operations as a merged entity. The achievement of these milestones has further consolidated the Company’s ambitions to become a leading developer and producer of non-invasive clinical solutions and products for the monitoring and management of a range of respiratory conditions, including asthma, sleep apnoea and emphysema. The asthma products are the first to reach the commercial marketplace and remain the Company’s current focus..."

 

Annual Report 2007

"The 2006/07 financial year was one of transition for KarmelSonix Ltd (“KSX”), incorporating a move into the area of respiratory medicine, combined with a strong focus on early commercialisation of the novel devices being developed by the Company..."